Combination of BTK Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant AML

Clinical trial NCT03642236 · UNKNOWN

Trial details

NCT number: NCT03642236
Sponsor: Nanfang Hospital, Southern Medical University
Status: UNKNOWN
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

FLT3-ITD Mutation Acute Myeloid Leukemia Brutons Tyrosine Kinase

Start date: 2018-08-01
Primary completion: 2022-08-01
Enrollment: 122

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.